Boosting predictors of prognosis of head and neck cancer
Head and neck cancer (HNC) is one of the most common types of cancer in Europe. More than 150 000 new patients are diagnosed each year. Even though it is the sixth most common cancer in Europe and South America, there is little awareness of this, with patient outcomes remaining poor for those diagnosed in the later stages. Accurate assessment of the prognosis of HNC cases also allows for appropriate treatment decisions. The EU-funded HEADSpAcE project will investigate the reasons for late diagnosis in Europe and South America. It will provide genomic evidence of strong predictors of prognosis that will have the potential to improve care and reduce treatment-related morbidity.
Call for proposal
See other projects for this call
Funding SchemeRIA - Research and Innovation action
70058 900 Brasilia